Patents by Inventor George Blanch Ewan

George Blanch Ewan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6569883
    Abstract: The invention relates to the use of compounds of the general formula (I) wherein R1 represents a hydrogen atom or a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-(C1-4)alkyl, C3-6 alkenyl, C3-10 alkynyl, phenyl or phenyl-C1-3 alkyl group; and one of the groups represented by R2, R3 and R4 is a hydrogen atom or a C1-6 alkyl, C3-7cycloalkyl, C2-6 alkenyl or phenyl-C1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C1-6 alkyl group; and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: May 27, 2003
    Assignee: Glaxo Group Limited
    Inventors: Michael Brian Tyers, Ian Harold Coates, David Cedric Humber, George Blanch Ewan, James Angus Bell
  • Patent number: 5925624
    Abstract: The present invention relates to 2,6-diaminopurine-.beta.-D-ribofuranuronamide derivatives of the following formula (I). These compounds and their salts and solvates are useful as anti-inflammatory agents, particularly in the treatment of patients with inflammatory conditions who are susceptible to leukocyte-induced tissue damage.
    Type: Grant
    Filed: September 18, 1995
    Date of Patent: July 20, 1999
    Assignee: Glaxo Group Limited
    Inventors: Michael Gregson, Barry Edward Ayres, deceased, George Blanch Ewan, Frank Ellis, John Knight
  • Patent number: 5922749
    Abstract: The invention relates to the use of compounds of the general formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-(C.sub.1-4) alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group; and one of the groups represented byR.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group;and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose. Promotion of gastric emptying may be for the relief of gastro-intestinal disorders associated with gastric stasis or may be of advantage in radiological examination procedures.
    Type: Grant
    Filed: August 16, 1996
    Date of Patent: July 13, 1999
    Assignee: Glaxo Group Limited
    Inventors: Michael Brian Tyers, Ian Harold Coates, David Cedric Humber, George Blanch Ewan, James Angus Bell
  • Patent number: 5889178
    Abstract: The present invention relates to compounds of formula (IV): ##STR1## wherein R.sup.a and R.sup.b each represent a hydrogen atom or together form an alkylidene group.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: March 30, 1999
    Assignee: Glaxo Group Limited
    Inventors: Michael Gregson, Barry Edward Ayres, deceased, George Blanch Ewan, Frank Ellis, John Knight